UA82828C2 - The use of enantiomeric pure escitalopram for treatment of depression - Google Patents

The use of enantiomeric pure escitalopram for treatment of depression

Info

Publication number: UA82828C2
Authority: UA; Ukraine
Prior art keywords: treatment; depression; disorders; disorder; enantiomeric pure
Prior art date: 2001-05-01

Application number

UA2003098415A

Other languages

English (en)

Inventor

Connie Sanchez

Arne Moerk

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-01

Filing date

2002-05-01

Publication date

2008-05-26

2002-05-01 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2008-05-26 Publication of UA82828C2 publication Critical patent/UA82828C2/xx

Links

208000020401 Depressive disease Diseases 0.000 title abstract 2
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title abstract 2
229960004341 escitalopram Drugs 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
208000024714 major depressive disease Diseases 0.000 abstract 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
208000032841 Bulimia Diseases 0.000 abstract 1
206010006550 Bulimia nervosa Diseases 0.000 abstract 1
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
206010013654 Drug abuse Diseases 0.000 abstract 1
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
208000030990 Impulse-control disease Diseases 0.000 abstract 1
206010029333 Neurosis Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
208000031674 Traumatic Acute Stress disease Diseases 0.000 abstract 1
208000026345 acute stress disease Diseases 0.000 abstract 1
208000022531 anorexia Diseases 0.000 abstract 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
235000014632 disordered eating Nutrition 0.000 abstract 1
208000024732 dysthymic disease Diseases 0.000 abstract 1
208000015238 neurotic disease Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
208000019899 phobic disease Diseases 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)

UA2003098415A 2001-05-01 2002-05-01 The use of enantiomeric pure escitalopram for treatment of depression UA82828C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200100684		2001-05-01
PCT/DK2002/000281 WO2002087566A1 (en)	2001-05-01	2002-05-01	The use of enantiomeric pure escitalopram

Publications (1)

Publication Number	Publication Date
UA82828C2 true UA82828C2 (en)	2008-05-26

Family

ID=8160464

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003098415A UA82828C2 (en)	2001-05-01	2002-05-01	The use of enantiomeric pure escitalopram for treatment of depression

Country Status (25)

Country	Link
US (7)	US20040198809A1 (pl)
EP (1)	EP1385503A1 (pl)
JP (1)	JP2004527551A (pl)
KR (2)	KR20100012089A (pl)
CN (1)	CN1509169A (pl)
AR (1)	AR033308A1 (pl)
AT (1)	AT10974U1 (pl)
BG (1)	BG108379A (pl)
BR (1)	BR0208283A (pl)
CA (1)	CA2445843A1 (pl)
CZ (1)	CZ20033267A3 (pl)
EA (1)	EA200301195A1 (pl)
HR (1)	HRP20030744A2 (pl)
HU (1)	HUP0400054A3 (pl)
IL (1)	IL158031A0 (pl)
IS (1)	IS6954A (pl)
ME (1)	MEP5908A (pl)
MX (1)	MXPA03008777A (pl)
NO (1)	NO20034538L (pl)
PL (1)	PL367480A1 (pl)
SK (1)	SK14612003A3 (pl)
UA (1)	UA82828C2 (pl)
WO (1)	WO2002087566A1 (pl)
YU (1)	YU85303A (pl)
ZA (1)	ZA200307102B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
CA2445843A1 (en) *	2001-05-01	2002-11-07	H. Lundbeck A/S	The use of enantiomeric pure escitalopram
NZ540281A (en) *	2002-12-23	2008-07-31	Lundbeck & Co As H	Escitalopram hydrobromide and a method for the preparation thereof
US20050037983A1 (en) *	2003-03-11	2005-02-17	Timothy Dinan	Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) *	2003-07-04	2006-01-25	Lundbeck & Co As H	La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
PT1691811E (pt) *	2003-12-11	2014-10-30	Sunovion Pharmaceuticals Inc	Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
NZ549100A (en) *	2004-03-05	2010-02-26	Lundbeck & Co As H	Crystalline composition containing escitalopram oxalate
US20050196453A1 (en)	2004-03-05	2005-09-08	H. Lundbeck A/S	Crystalline composition containing escitalopram
TWI358407B (en) *	2005-06-22	2012-02-21	Lundbeck & Co As H	Crystalline base of escitalopram and orodispersibl
AU2006304889A1 (en) *	2005-10-14	2007-04-26	H. Lundbeck A/S	Stable pharmaceutical formulations containing escitalopram and bupropion
KR20080080094A (ko) *	2005-10-14	2008-09-02	하. 룬트벡 아크티에 셀스카브	에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
US20070134322A1 (en) *	2005-12-14	2007-06-14	Forest Laboratories, Inc.	Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) *	2006-01-05	2007-12-12	昆明积大制药有限公司	含西酞普兰和环糊精的抗抑郁口服药用组合物
TW200812993A (en) *	2006-05-02	2008-03-16	Lundbeck & Co As H	New uses of escitalopram
US20070259952A1 (en) *	2006-05-02	2007-11-08	H. Lundbeck A/S	Uses of escitalopram
US8252336B2 (en) *	2006-10-20	2012-08-28	Ratiopharm Gmbh	Escitalopram and solid pharmaceutical composition comprising the same
US20100003313A1 (en) *	2006-10-27	2010-01-07	Hisamitsu Pharmaceutical Co.,Inc.	Adhesive skin patch
EP2017271A1 (en)	2007-07-06	2009-01-21	Aurobindo Pharma Limited	Process for the preparation of escitalopram
ES2653852T3 (es) *	2007-08-03	2018-02-09	Richter Gedeon Nyrt.	Composiciones farmacéuticas que contienen ligandos del receptor de dopamina y procedimientos de tratamiento usando ligandos del receptor de dopamina
CA2713598C (en) *	2008-01-31	2016-07-05	Takeda Pharmaceutical Company Limited	Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
ITMI20080768A1 (it) *	2008-04-24	2009-10-25	Abiogen Pharma Spa	Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
WO2010098230A1 (ja) *	2009-02-27	2010-09-02	久光製薬株式会社	経皮投与製剤
US20180071269A1 (en)	2015-08-12	2018-03-15	Tianxin Wang	Therapeutical methods, formulations and nutraceutical formulations
CA2982898C (en) *	2015-05-13	2023-08-29	A. Carlsson Research Ab	Combination of dopamine stabilizing agent and an anti-depressive agent to treat a disorder characterized by debilitating fatigue

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1143703A (pl) *	1965-03-18
US4079135A (en) *	1973-12-13	1978-03-14	Imperial Chemical Industries Limited	Morpholine derivatives as antidepressants
GB1526331A (en) *	1976-01-14	1978-09-27	Kefalas As	Phthalanes
GB8419963D0 (en) *	1984-08-06	1984-09-12	Lundbeck & Co As H	Intermediate compound and method
GB8607313D0 (en) *	1986-03-25	1986-04-30	Ici Plc	Pharmaceutical compositions
GB8814057D0 (en) *	1988-06-14	1988-07-20	Lundbeck & Co As H	New enantiomers & their isolation
US4902710A (en) *	1988-12-14	1990-02-20	Eli Lilly And Company	Serotonin and norepinephrine uptake inhibitors
US5114976A (en) *	1989-01-06	1992-05-19	Norden Michael J	Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) *	1989-11-02	1990-10-09	Pfizer Inc.	Method of treating anxiety-related disorders using sertraline
US5296507A (en) *	1990-09-06	1994-03-22	H.Lundbeck A/S	Treatment of cerbrovascular disorders
US5708035A (en) *	1991-02-04	1998-01-13	Sepracor Inc.	Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) *	1994-11-28	1997-01-15	Lilly Co Eli	Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) *	1995-01-17	1997-05-06	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5554383A (en) *	1995-04-06	1996-09-10	Trustees Of Tufts College	Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) *	1995-04-27	1995-04-27	Astra Ab	A new combination
US5846982A (en) *	1996-06-14	1998-12-08	Eli Lilly And Company	Inhibition of serotonin reuptake
US5747494A (en) *	1996-06-28	1998-05-05	U C B S.A.	Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) *	1996-08-16	1999-09-28	Eli Lilly And Company	Potentiation of serotonin response
ZA977967B (en) *	1996-09-23	1999-03-04	Lilly Co Eli	Combination therapy for treatment of psychoses
US5776969A (en) *	1997-02-27	1998-07-07	Eli Lilly And Company	Treatment of sleep disorders
US6069177A (en) *	1997-07-08	2000-05-30	The Hong Kong University Of Science And Technology	3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) *	1997-09-18	1997-09-18	Astra Ab	A new combination
CN1286687A (zh) *	1997-11-11	2001-03-07	H·隆德贝克有限公司	制备西酞普兰的方法
EP1100501A4 (en) *	1998-06-30	2002-12-04	Lilly Co Eli	PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
US6150376A (en) *	1998-08-05	2000-11-21	Georgetown University	Bi- and tri-cyclic aza compounds and their uses
WO2000023431A1 (en) *	1998-10-20	2000-04-27	H. Lundbeck A/S	Method for the preparation of citalopram
IL145615A0 (en) *	1999-04-14	2002-06-30	Lundbeck & Co As H	Method for the preparation of citalopram
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
US6333357B1 (en) *	1999-11-05	2001-12-25	Be Able, Llc	Behavior chemotherapy
UA77650C2 (en) *	1999-12-06	2007-01-15	Lundbeck & Co As H	Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) *	2000-03-13	2002-01-30	Lundbeck & Co As H	Crystalline base of citalopram
US6469064B2 (en) *	2000-04-24	2002-10-22	Aryx Therapeutics	Materials and methods for the treatment of depression
CA2445843A1 (en) *	2001-05-01	2002-11-07	H. Lundbeck A/S	The use of enantiomeric pure escitalopram

2002
- 2002-05-01 CA CA002445843A patent/CA2445843A1/en not_active Abandoned
- 2002-05-01 HU HU0400054A patent/HUP0400054A3/hu unknown
- 2002-05-01 MX MXPA03008777A patent/MXPA03008777A/es unknown
- 2002-05-01 ME MEP-59/08A patent/MEP5908A/xx unknown
- 2002-05-01 CZ CZ20033267A patent/CZ20033267A3/cs unknown
- 2002-05-01 HR HR20030744A patent/HRP20030744A2/xx not_active Application Discontinuation
- 2002-05-01 WO PCT/DK2002/000281 patent/WO2002087566A1/en not_active Ceased
- 2002-05-01 BR BR0208283-7A patent/BR0208283A/pt not_active IP Right Cessation
- 2002-05-01 SK SK1461-2003A patent/SK14612003A3/sk not_active Application Discontinuation
- 2002-05-01 IL IL15803102A patent/IL158031A0/xx unknown
- 2002-05-01 US US10/468,685 patent/US20040198809A1/en not_active Abandoned
- 2002-05-01 KR KR1020097027003A patent/KR20100012089A/ko not_active Ceased
- 2002-05-01 PL PL02367480A patent/PL367480A1/pl not_active Application Discontinuation
- 2002-05-01 CN CNA028092309A patent/CN1509169A/zh active Pending
- 2002-05-01 EP EP02724141A patent/EP1385503A1/en not_active Withdrawn
- 2002-05-01 KR KR10-2003-7014286A patent/KR20040030609A/ko not_active Ceased
- 2002-05-01 EA EA200301195A patent/EA200301195A1/ru unknown
- 2002-05-01 UA UA2003098415A patent/UA82828C2/xx unknown
- 2002-05-01 JP JP2002584912A patent/JP2004527551A/ja active Pending
- 2002-05-01 YU YU85303A patent/YU85303A/sh unknown
- 2002-05-02 AR ARP020101612A patent/AR033308A1/es unknown
2003
- 2003-08-20 US US10/644,577 patent/US20040198810A1/en not_active Abandoned
- 2003-08-20 US US10/644,579 patent/US20040192765A1/en not_active Abandoned
- 2003-08-20 US US10/644,588 patent/US20040192766A1/en not_active Abandoned
- 2003-08-20 US US10/644,587 patent/US20040198811A1/en not_active Abandoned
- 2003-08-20 US US10/644,576 patent/US20040192764A1/en not_active Abandoned
- 2003-09-11 ZA ZA200307102A patent/ZA200307102B/xx unknown
- 2003-09-15 IS IS6954A patent/IS6954A/is unknown
- 2003-10-09 NO NO20034538A patent/NO20034538L/no not_active Application Discontinuation
- 2003-11-24 BG BG108379A patent/BG108379A/bg unknown
2007
- 2007-09-12 US US11/853,949 patent/US20080004338A1/en not_active Abandoned
2008
- 2008-03-21 AT AT0017508U patent/AT10974U1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
EA200301195A1 (ru)	2004-04-29
CA2445843A1 (en)	2002-11-07
EP1385503A1 (en)	2004-02-04
HUP0400054A2 (hu)	2004-04-28
BG108379A (bg)	2004-11-30
US20040198809A1 (en)	2004-10-07
AT10974U1 (de)	2010-02-15
MXPA03008777A (es)	2004-02-12
BR0208283A (pt)	2004-03-09
HUP0400054A3 (en)	2007-03-28
IL158031A0 (en)	2004-03-28
NO20034538D0 (no)	2003-10-09
US20040192765A1 (en)	2004-09-30
IS6954A (is)	2003-09-15
YU85303A (sh)	2006-05-25
KR20040030609A (ko)	2004-04-09
SK14612003A3 (sk)	2004-04-06
PL367480A1 (pl)	2005-02-21
US20040192766A1 (en)	2004-09-30
JP2004527551A (ja)	2004-09-09
MEP5908A (xx)	2010-02-10
CZ20033267A3 (en)	2004-06-16
US20080004338A1 (en)	2008-01-03
US20040198811A1 (en)	2004-10-07
CN1509169A (zh)	2004-06-30
WO2002087566A1 (en)	2002-11-07
KR20100012089A (ko)	2010-02-05
ZA200307102B (en)	2004-09-13
US20040198810A1 (en)	2004-10-07
AR033308A1 (es)	2003-12-10
NO20034538L (no)	2003-10-09
HRP20030744A2 (en)	2005-06-30
US20040192764A1 (en)	2004-09-30

Publication	Publication Date	Title
YU85303A (sh)	2006-05-25	Upotreba enantiomerno čistog escitaloprama
NO20100333L (no)	2002-01-07	Behandling av nevrotiske forstyrrelser
MXPA03010232A (es)	2004-03-16	Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
IL158590A0 (en)	2004-05-12	Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
DE69428791D1 (de)	2001-11-29	Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden
NO20052348L (no)	2005-08-02	Behandling av hemoragisk sjokk
ATE450622T1 (de)	2009-12-15	Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit
SG131109A1 (en)	2007-04-26	Muteins of tear lipocalin
DK1163224T3 (da)	2003-08-04	N-[2-hydroxy-3-(1-piperiinyl)propoxy]pyridin-1-oxid-3-carboximidoylchlorid og dets anvendelse i behandlingen af insulinresistens
EE200400005A (et)	2004-02-16	Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
WO2002081745A3 (en)	2003-10-23	Genes involved in osteogenesis, and methods of use
SE0102147D0 (sv)	2001-06-18	New methods
DE69520430D1 (de)	2001-04-26	Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
JP2006514952A5 (pl)	2007-01-18
WO2003039468A3 (en)	2003-10-23	Antimnemonic therapy for hypermemory syndromes
MY136683A (en)	2008-11-28	Kappa opoid agonist for the treatment of irritable bladder
ATE408602T1 (de)	2008-10-15	Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
MXPA04010816A (es)	2005-03-07	Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
WO2005056056A3 (en)	2006-02-02	The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
DE60034110D1 (de)	2007-05-10	Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE60215219D1 (de)	2006-11-16	Verwendung von darifenacin zur behandlung des harndrangs
ATE399544T1 (de)	2008-07-15	Synergistische zusammensetzung enthaltend roflumilast und (r,r)-formoterol
ATE380884T1 (de)	2007-12-15	Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
WO2004026236A3 (en)	2004-06-03	Cyclopentyl indole derivatives
WO2003027295A3 (en)	2003-10-16	Methods for diagnosis and treatment of diseases associated with altered expression of jak1